Switch theme
Sign up to access all valuation multiples
Alembic Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company focuses on manufacturing and marketing generic pharmaceutical products across the globe. Alembic also operates a branded formulation business that covers a range of therapeutic areas such as dermatology, oncology, ophthalmology, and injectable formulations. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
2010
14.9K+
LTM Revenue $761M
LTM EBITDA $121M
$2.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Alembic Pharmaceuticals has a last 12-month revenue of $761M and a last 12-month EBITDA of $121M.
In the most recent fiscal year, Alembic Pharmaceuticals achieved revenue of $710M and an EBITDA of $112M.
Alembic Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Alembic Pharmaceuticals valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $639M | $710M | XXX | XXX | XXX |
| Gross Profit | $408M | $404M | XXX | XXX | XXX |
| Gross Margin | 64% | 57% | XXX | XXX | XXX |
| EBITDA | $79.0M | $112M | XXX | XXX | XXX |
| EBITDA Margin | 12% | 16% | XXX | XXX | XXX |
| Net Profit | $60.5M | $39.7M | XXX | XXX | XXX |
| Net Margin | 9% | 6% | XXX | XXX | XXX |
| Net Debt | $66.1M | $65.1M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Alembic Pharmaceuticals's stock price is INR 847 (or $10).
Alembic Pharmaceuticals has current market cap of INR 167B (or $1.9B), and EV of INR 176B (or $2.0B).
See Alembic Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.0B | $1.9B | XXX | XXX | XXX | XXX | $0.34 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Alembic Pharmaceuticals has market cap of $1.9B and EV of $2.0B.
Alembic Pharmaceuticals's trades at 2.7x LTM EV/Revenue multiple, and 16.8x LTM EBITDA.
Analysts estimate Alembic Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Alembic Pharmaceuticals and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $2.0B | XXX | XXX | XXX |
| EV/Revenue | 2.7x | XXX | XXX | XXX |
| EV/EBITDA | 17.3x | XXX | XXX | XXX |
| P/E | 28.5x | XXX | XXX | XXX |
| P/E/Growth | 1.3x | XXX | XXX | XXX |
| EV/FCF | 47.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAlembic Pharmaceuticals's NTM/LTM revenue growth is 11%
Alembic Pharmaceuticals's revenue per employee for the last fiscal year averaged $48K, while opex per employee averaged $27K for the same period.
Over next 12 months, Alembic Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Alembic Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Alembic Pharmaceuticals and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 11% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 16% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 41% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 27% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $48K | XXX | XXX | XXX | XXX |
| Opex per Employee | $27K | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 16% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 4% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 0% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 56% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Alembic Pharmaceuticals acquired XXX companies to date.
Last acquisition by Alembic Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Alembic Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Alembic Pharmaceuticals founded? | Alembic Pharmaceuticals was founded in 2010. |
| Where is Alembic Pharmaceuticals headquartered? | Alembic Pharmaceuticals is headquartered in India. |
| How many employees does Alembic Pharmaceuticals have? | As of today, Alembic Pharmaceuticals has 14.9K+ employees. |
| Who is the CEO of Alembic Pharmaceuticals? | Alembic Pharmaceuticals's CEO is Mr. Chirayu R. Amin. |
| Is Alembic Pharmaceuticals publicy listed? | Yes, Alembic Pharmaceuticals is a public company listed on BOM. |
| What is the stock symbol of Alembic Pharmaceuticals? | Alembic Pharmaceuticals trades under 533573 ticker. |
| When did Alembic Pharmaceuticals go public? | Alembic Pharmaceuticals went public in 2011. |
| Who are competitors of Alembic Pharmaceuticals? | Similar companies to Alembic Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Alembic Pharmaceuticals? | Alembic Pharmaceuticals's current market cap is $1.9B |
| What is the current revenue of Alembic Pharmaceuticals? | Alembic Pharmaceuticals's last 12-month revenue is $761M. |
| What is the current EBITDA of Alembic Pharmaceuticals? | Alembic Pharmaceuticals's last 12-month EBITDA is $121M. |
| What is the current EV/Revenue multiple of Alembic Pharmaceuticals? | Current revenue multiple of Alembic Pharmaceuticals is 2.7x. |
| What is the current EV/EBITDA multiple of Alembic Pharmaceuticals? | Current EBITDA multiple of Alembic Pharmaceuticals is 16.8x. |
| What is the current revenue growth of Alembic Pharmaceuticals? | Alembic Pharmaceuticals revenue growth between 2023 and 2024 was 11%. |
| Is Alembic Pharmaceuticals profitable? | Yes, Alembic Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
